AOX1 Biomarker Detection for Placental Aging and Stillbirth Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to detect oxidative stress and aging in placental tissue, which can lead to stillbirth, and there is no reliable way to determine the optimal gestational window for pregnancy, increasing the risk of post-maturity syndrome and stillbirth.
Innovation Solution
Measuring aldehyde oxidase 1 (AOX1) expression and activity levels, along with markers like 4-hydroxynonenal, in biological samples to assess placental oxidative stress, allowing for non-invasive prediction of stillbirth risk and potential interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pregnancy is extended beyond term to allow further fetal development, then fetal maturity and development are improved, but the risk of stillbirth and post-maturity complications increases exponentially
Solution Approach 1:
The patent applies preliminary action by measuring AOX1 expression levels and oxidative stress markers during pregnancy to predict placental aging and stillbirth risk before adverse events occur. This allows clinicians to intervene proactively by timing delivery at the optimal moment - extending pregnancy as long as safety permits while preventing stillbirth by detecting aging signs early. The method enables personalized determination of the optimal gestational window for each pregnancy.
2Measurement precision
If placental tissue is biopsied to assess oxidative stress and aging, then diagnostic accuracy is improved, but invasive procedures and fetal risk increase
Solution Approach 1:
The patent applies the extraction principle by isolating and measuring specific oxidative stress markers (AOX1 expression, 4-hydroxynonenal levels, 8-hydroxy-deoxyguanosine) from placental tissue or maternal blood samples. Instead of requiring comprehensive tissue analysis, the method extracts and quantifies these specific molecular markers that reliably indicate placental aging and oxidative stress, achieving high diagnostic precision with minimal invasive sampling.
Solution Approach 2:
The patent uses maternal blood as an intermediary medium to indirectly assess placental oxidative stress. Rather than directly sampling placental tissue, the method measures AOX1 expression and oxidative markers in maternal circulation, which reflect placental status. This intermediary approach eliminates the need for invasive placental biopsies while maintaining diagnostic accuracy.
3Object-affected harmful factors
If delivery is induced early to prevent stillbirth risk, then fetal safety is improved, but fetal development maturity may be compromised
Solution Approach 1:
The patent applies feedback by continuously monitoring AOX1 expression levels and oxidative stress markers throughout pregnancy to dynamically assess placental aging status. This real-time feedback allows clinicians to adjust delivery timing based on actual placental condition rather than fixed gestational dates. When markers indicate healthy placental function, pregnancy can be extended; when markers show aging or oxidative stress, delivery is triggered, optimizing the balance between fetal safety and development maturity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a reliable biomarker for detecting placental aging and oxidative stress, enabling timely interventions to prevent stillbirth and optimizing pregnancy duration, thereby reducing the risk of post-maturity complications.
Implementation Method 1
aldehyde oxidase 1 (AOX1) expression and activity (and levels of markers thereof such as 4-hydroxynonenal, 4HNE) correlates with tissue aging and oxidative damage
Data Source
AI summary
Provided herein are methods of detecting or determining aging and/or oxidative damage in tissue, including placental tissue, skin, kidney and brain tissue. One embodiment provides a method for detecting or determining aging in body tissue, comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample, wherein the level of AOX1 expression or activity, or of the one or more markers, is indicative of aging in the tissue. Also provided herein are methods of treating a disease or condition associated with ageing or oxidative damage in one or more cells or tissues, comprising administering to a subject in need thereof an inhibitor of AOX1.